New findings about covid vaccine6/22/2023 Next year, the company has said it plans to make between 500 million and 1 billion doses of the vaccine. The rollout will be quick because Moderna has already begun manufacturing of the vaccine, and has said that it plans to have 20 million doses by the end of 2020. If the vaccine receives an Emergency Use Authorization from the FDA in the next few weeks, Bancel says that the first doses could be distributed as early as late December of this year. If approved, the vaccine should be generally available next year Moderna has also signed a $1.5 billion agreement with the federal government to purchase 100 million doses of its vaccine once it’s been approved. (By contrast, Pfizer spent around $1 billion of its own money to develop its vaccine). That was a big boost to the company, which had posted a net loss of $514 million on revenues of just $60 million last year. Moderna got a big boost in development cash from the Federal governmentĪs part of the Federal government’s “Operation Warp Speed,” Moderna received nearly $1 billion in support from the Federal government to develop its Covid-19 vaccine, in addition to approval to begin human trials before animal safety testing had completed. To that end, Moderna has said that it plans to submit an application for an Emergency Use Authorization to the Food & Drug Administration “in the coming weeks.” Applications to other regulatory bodies around the world will follow shortly thereafter. Update 11/30/20: Moderna announced today that it has filed for Emergency Use Authorization with the FDA.īefore any vaccine can be distributed to the public, it first has to be authorized by the appropriate regulatory bodies. MORE FROM FORBES Moderna CEO: Covid-19 Vaccine's 'Fantastic' Results Mean It Could Be Ready Next Month By Leah Rosenbaum The vaccine still needs to be approved by regulatory authorities “There seems to be a pattern with the mRNA vaccines which suggests the technology is pretty helpful for infectious disease.” If the numbers hold up when the vaccine’s released to the general public, that suggests they may be significantly better than seasonal flu vaccines, which typically only have efficacy in the range of 40-60%. The outcome is “pretty impressive,” agrees Needham biotech analyst Alan Carr. “When you look at the severe disease, it’s what gets me most excited,” says Moderna CEO Stéphane Bancel. That suggests that even if the vaccine doesn’t fully protect you from getting infected, it may prevent the worst forms of the disease. No one who was given the vaccine had a severe case of Covid-19, compared to 11 people who got the placebo. In a placebo group, 90 of 95 patients became infected with Covid-19, while only 5 out of 95 who were given the vaccine got infected. The actual data from the clinical trial has not yet been released or peer-reviewed, though the company said it plans to do so. In a press release, Moderna announced that its mRNA vaccine was about 95% effective at preventing Covid-19 in a trial of 30,000 people across the U.S. Preliminary results suggest mRNA vaccines are very effective
0 Comments
Leave a Reply. |